John D Henley1, Oscar W Cummings, Patrick J Loehrer. 1. Department of Pathology, Indiana University School of Medicine, Clarian Health Partners, 550 North University Blvd, Rm 3465, Indianapolis 46202, USA. jhenley@iupui.edu
Abstract
PURPOSE: Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors. METHODS: Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma). RESULTS: In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas). CONCLUSIONS: An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.
PURPOSE: Promising new therapies for neoplasia include tyrosine kinase receptor antagonists. Tyrosine kinase oncogenes present an appealing anti-tumor drug target since they play an integral role in a variety of cellular responses including cell proliferation and differentiation. We previously demonstrated a high rate of epidermal growth factor receptor (EGFR) expression in advanced-stage thymic epithelial tumors. More recently, we have examined c-KIT (CD117) expression in a similar series of tumors. METHODS:Tumor from 35 patients seen at our institution for treatment of advanced-stage thymoma was available. Twenty thymomas and 15 thymic carcinomas were assessed for c-KIT expression. Tissue sections of tumor were stained immunohistochemically with anti-c-KIT (Oncogene). Either cytoplasmic or membrane staining was considered positive. Appropriate controls were performed. Positive staining for c-KIT was present in 12 tumors (11 thymic carcinomas and 1 thymoma). RESULTS: In distinction to EGFR, c-KIT is expressed more commonly in thymic carcinomas (73% of carcinomas) than in thymoma (5% of thymomas). CONCLUSIONS: An EGFR negative/c-KIT positive staining pattern is typical of thymic carcinoma, whereas thymomas are generally EGFR positive/c-KIT negative. Possible therapeutic implications of these observations remain to be determined.
Authors: R P Takes; R J Baatenburg de Jong; E Schuuring; S V Litvinov; J Hermans; J H Van Krieken Journal: Anticancer Res Date: 1998 Nov-Dec Impact factor: 2.480
Authors: P Stanton; S Richards; J Reeves; M Nikolic; K Edington; L Clark; G Robertson; D Souter; R Mitchell; F J Hendler Journal: Br J Cancer Date: 1994-09 Impact factor: 7.640
Authors: Seena C Aisner; Suzanne Dahlberg; Meera R Hameed; David S Ettinger; Joan H Schiller; David H Johnson; Joseph Aisner; Patrick J Loehrer Journal: J Thorac Oncol Date: 2010-06 Impact factor: 15.609
Authors: Nicolas Girard; Ronglai Shen; Tianhua Guo; Maureen F Zakowski; Adriana Heguy; Gregory J Riely; James Huang; Christopher Lau; Alex E Lash; Marc Ladanyi; Agnes Viale; Cristina R Antonescu; William D Travis; Valerie W Rusch; Mark G Kris; William Pao Journal: Clin Cancer Res Date: 2009-10-27 Impact factor: 12.531